Transfusion Research

Transfusion Research Unit (TRU)

Investigators

Professor Erica Wood, Professor Peter Cameron, Professor John McNeil, A/Prof Zoe McQuilten

News

Click here for the latest TRU news.

Overview

Blood sampleThe Transfusion Research Unit (TRU) was established in 2008 to provide a research focus on the use of blood transfusions in different clinical settings, especially in the treatment of rare blood conditions. TRU has developed ongoing collaborations with various state, national and international partners. These include health departments, organisations, and institutions including the Victorian Department of Health and Human Services, the National Blood Authority, Australian Red Cross Blood Service, New Zealand Blood Service and industry partners.

TRU works closely with clinical leaders to establish national clinical quality registries and other projects to collect information about conditions requiring major and/or complex transfusion support, and to better understand and improve outcomes for patients.

Clinical experts from around Australia and New Zealand participate as local investigators and project steering committee members. TRU also has close links with governments, advisory groups, specialty Colleges and professional societies to ensure translation of research into policy and practice.

Current research registries

Clinical trials

  • TREATT: Trial to evaluate anti-fibrinolytic therapy in thrombocytopenia, a collaborative RCT with NHS Blood and Transplant that explores the efficacy and safety of tranexamic acid to limit bleeding in people with haematologic malignancies and low platelet counts.
  • RATIONAL: Role of antibiotic therapy or IVIg on infections in haematology, a National Blood Authority funded trial ascertaining the safety and efficacy of oral antibiotics or intravenous immunoglobulin to reduce infection risk in adults with haematologic malignancies and low immunoglobulin levels. Data will inform a future large scale RCT.
  • REDDS: Red blood cell transfusion thresholds and QoL in myelodysplastic syndromes. The REDDS-1 feasibility trial of haemoglobin thresholds for red cell transfusion in transfusion-dependent myelodysplastic syndromes (MDS) was presented at the American Society of Hematology in December 2018. Building one these results, the REDDS-2 two-part trial will assess a novel weekly transfusion schedule, using matched red cells, in patients with transfusion-dependent MDS. Clinical functional outcome and quality of life, as well as red cell use, will be evaluated. Patient and healthcare worker experiences will be explored via a qualitative study. REDDS is a collaboration between Monash University, the UK National Health Service Blood and Transplant (NHSBT) and hospitals in Australia and the UK. The results will inform the design and conduct of an international phase III trial. REDDS2 is funded by the Australian & New Zealand Society of Blood Transfusion, and Monash Haematology.
  • DIAAMOND project: Diagnosis of Aplastic Anaemia, Management, and Outcomes utilising a National Dataset. A national registry-based clinical trial using a novel adaptive (Bayesian) study design, to investigate the benefit and costs of avatrombopag, a second-generation thrombopoietin receptor agonist, in addition to conventional immunosuppressive therapies, in Aplastic Anaemia.
  • ITACS: IV iron for treatment of anaemia before cardiac surgery, in collaboration with The Alfred, this is an international RCT comparing efficacy, safety and cost effectiveness of preoperative intravenous iron in cardiac surgery patients with anaemia funded by the NHMRC and ANZCA.
  • Life-threatening massive obstetric haemorrhage requiring rapid, high-volume blood transfusion: In collaboration with AMOSS, this is a prospective, population-based case control study across Australia and New Zealand investigating factors contributing to major obstetric haemorrhages and their management.
  • AMARC: The Australasian Myeloma Research Consortium (AMaRC) aims to promote, facilitate and sponsor multi-centre investigator initiated trials and collaborative laboratory research projects in myeloma, acting as a trial centre supporting the participating sites in Australasia.
  • APAC MRDR: Asia-Pacific (APAC) expansion of the Australia and New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) to Korea, Singapore, Hong Kong and Taiwan using the existing infrastructure and project design. This expansion will be used to investigate a wide range of research questions, including relating to access to specialised myeloma care, variation in clinical practice, uptake of targeted therapies and participation in clinical trials.

Other transfusion projects

  • Data linkage: in collaboration with established large clinical registries (for trauma, intensive care and cardiac surgery) we use data from these sources as well as administrative datasets (such as hospital admissions) and link with laboratory information to develop models to predict and monitor blood use.
  • Systematic reviews: in collaboration with Oxford's Systematic Reviews Initiative team we undertake systematic reviews to better understand the current evidence base for transfusion practice and identify evidence gaps for future research.
  • New activities include exploration of the implementation of new national patient blood management guidelines.

Collaborations

  • Australasian Leukaemia and Lymphoma Group: A/Prof Zoe McQuilten is a member of the ALLG Scientific Advisory Committee and chair of the Supportive Care Disease Group. Prof Erica Wood is a member of the Supportive Care Disease Group.
  • Australian and New Zealand Society of Blood Transfusion: Prof Erica Wood is former president of ANZSBT and a member of the ANZSBT Research Committee. Mrs Helen Haysom is a member of the ANZSBT transfusion science standing committee. Mr Neil Waters is a member of the ANZSBT education standing committee.
  • Biomedical Excellence for Safer Transfusion (BEST) Collaborative
  • Blood Matters: Prof Erica Wood is a member of the Blood Matters advisory committee and Serious Transfusion Incident Reporting (STIR) expert group.
  • International Collaboration for Transfusion Medicine Guidelines: ICTMG is an international network to develop evidence-based clinical guidelines to improve transfusion practice. Prof Erica Wood is a member of the ICTMG and its executive committee.
  • International Haemovigilance Network
  • International Society of Blood Transfusion: Many members of the TRU team are members of ISBT and participate in its working parties and activities. Prof Erica Wood is president-elect of ISBT.
  • NHS Blood and Transplant, United Kingdom
  • Transfusion Outcomes Research Collaborative (TORC): A partnership with the Australian Red Cross Blood Service. This collaboration, established in 2008, has been central to the design and progress of pioneering transfusion research in Australia. TORC is overseen by a multidisciplinary steering committee chaired by Professor Merrole Cole-Sinclair of St Vincent's Hospital, Melbourne. TORC's setting, combining access to transfusion medicine and research expertise, provides opportunities for medical specialists in training and future researchers to develop solid foundations in transfusion research methodologies.
  • University of Oxford
  • World Health Organization: Prof Erica Wood is a member of the WHO expert advisory panel on blood transfusion.

Staff

Naomi Aoki, Melissa Chee, Gemma Crighton, Amber Degelia, Vanessa Fox, Helen Haysom, Kelly Lai, Masa Lasica, Zoe McQuilten, Elizabeth Moore, Sally Nailon, Nicholas Saadah, Laura Sellick, Rosemary Sparrow, Gaya St George, Christianto Thu, Tina van Tonder, Neil Waters, Cameron Wellard, James Wilkie, Erica Wood

PhD students

Lucy Fox, Phil Kiely, Allison Mo

Adjunct appointment

Professor Merrole Cole-Sinclair